1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.

Company Interview / Junior miners & biotechs Keith is watching

Loading

Preparing video

Junior miners & biotechs Keith is watching

Company Interview31 Jul, 2025

Key points:

Copper sector volatility deemed overdone; seen as a short-term trading opportunity MP Materials secures US government and Apple investments, igniting activity in rare earths ASX companies Dateline Resources, Resolution Minerals ride US minerals boom Biotech stocks like Narada and Ibex Biologics attract interest after positive regulatory events

Keith Della-Vedova from CPS Capital sees significant volatility and opportunity in the resources sector, especially in light of the recent dramatic fall in copper prices. Della-Vedova attributes the steep 20% drop to overdone market reactions to anticipated tariffs and policy changes that, in his view, cannot be supported by current US processing capacity. He highlights the copper sector as presenting short-term trading opportunities, drawing parallels to recent moves in Boss Energy (ASX:BOE) and Grantland Gold (ASX:GRG), noting the potential for quick recoveries if the sector finds a base.

Della-Vedova emphasises heightened activity among junior miners and explorers, particularly in the US, where capital inflows are increasing amid strategic deals. He references a landmark transaction involving MP Materials and a multibillion-dollar US government agreement aimed at boosting rare earth magnet production, reducing China’s market control. Apple’s significant investment in MP Materials underscores the growing interest in downstream processing and recycling. Additional momentum has been seen in ASX-listed companies such as Dateline Resources (ASX:DTR) and Resolution Minerals (ASX:RML), which have experienced significant share price gains following high-profile endorsements and acquisitions.

Biotech also features prominently on Della-Vedova’s radar, with companies like Nyrada Inc (ASX:NYR) and IBX attracting capital and attention due to FDA milestones and strong liquidity. He points out that biotech events can deliver substantial returns for investors, appealing to those seeking high-impact growth.

Copyright © 2026 Ausbiz Capital
Junior miners & biotechs Keith is watching - Ausbiz Capital